ArticleTargeted oncology2026

Elranatamab Versus Teclistamab in Relapsed and Refractory Multiple Myeloma: A Real-World Propensity Score-Matched Study.

Yin-Che Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.